News & Events

Northern New England Clinical and Translational Research (NNE-CTR) successes, events and news.


Highlights

Funding Opportunities (Current List)

January 24, 2019 by Jennifer Smith

Click here for a curated and updated list of summaries of CTR-relevant funding opportunities.

Comprehensive Weekly Listings: NIH FOAs , Current RFAs , Current PAs
-----------------------------------------------------------
Advancing Cancer Immunotherapy by Mitigating Immune-related Adverse Events (U01)

FOA, RFA-CA-19-044, is to support improved cancer immunotherapy research projects that reduce the incidence and/or severity of immune-related adverse events (irAEs) while retaining anti-tumor efficacy. Single investigators and/or multidisciplinary teams with expertise in mechanisms of cancer immunology, immune tolerance, irAEs, autoimmunity, and/or patient characterization and selection are encouraged to propose projects that utilize appropriate model systems, clinical samples, and expertise of these research communities. The specific objectives are to generate new ideas and approaches to better understand and thereby reduce the incidence and/or severity of irAEs resulting from cancer immunotherapy.

Due April 25, 2019.
-----------------------------------------------------------

The NIH Pain Consortium is presenting two HEAL initiatives RFA-NS-19-010 and RFA-NS-19-020 .

The purpose of these funding opportunity announcement (FOA) are to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads towards clinical trials. Applicants must have a promising hit/lead, robust biological rationale for the intended approach, and identified assays for optimization of the agent. The scope of this program includes optimization and early development activities, IND-enabling studies, and assembly of Investigational New Drug (IND) application. This is a milestone-driven phased cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress.

Due March 6, 2019
------------------------------------------------------------
Genetics & Phenotypes Associated with Drug Abuse
FOA, PAR-18-789, Genetic analysis of non-human animal models to understand the genomic architecture of substance use disorders and addictive behaviors.  

The goals of this initiative are to discover allelic variants, genomic alterations, and functional changes associated with addictive behaviors in non-human animals through systems studies that employ genetic and genomics strategies. We also encourage applications that take genetic and/or genomics approaches to integrate data, delineate gene networks, and uncover the function of known or newly discovered genetic or epigenetic variants.

Investigators examining the phenotype of knockout mice are discouraged from submitting applications to this FOA. Instead, they should submit applications in response PA-17-155 (R01).
Due March 19, 2019.
-----------------------------------------------------------

The NIH Research Evaluation and Commercialization Hubs (REACH) Awards (RFA-OD-19-014) is a trans-NIH program and invites participation from IDeA states.  Through this program, NIH will provide the qualifying institutions with the funds to seed the creation of academic entrepreneurship Hubs. Hubs will be responsible for providing innovators with both the initial investment and resources to support the proof of concept work and the mentorship in product development and commercialization needed to develop high priority technologies that address the highest US disease burden within the NIH’s mission. Funded Hubs are intended to work as a consortium to enable: (1) the infrastructure for identifying the most promising technologies, (2) funding for product definition studies (e.g. feasibility studies, prototype development, proof-of-concept studies) provided to individual researchers, (3) access to expertise in areas required for early stage technology development (including scientific, regulatory, reimbursement, business, legal, and project management), and (4) skills development and hands-on experience in entrepreneurship.  Establishing public-private partnerships and providing additional non-federal funds will be critical for success.
Due March 19, 2019.

----------------------------------------------------------------
RFA-DK-19-001 Mass Spec Assays for the Reliable and Reproducible Detection of Proteins/Peptides in Obesity Research (U01)

The development of a single multiplexed assay that includes all proteins and peptides of potential interest to the obesity research community would be optimal but might not be feasible due to the different chemical physical characteristics of several of the proteins/peptides of interest.

This FOA invites applications proposing the development of targeted mass spectrometric assays for proteins and peptides of primary interest to the obesity research community. The goal should be to develop assays that are easily transferable to any laboratory that has appropriate expertise and access to a mass spectrometry facility. For this purpose, the use of easily accessible and inexpensive separation steps such as SPE and µElution is encouraged.
Due April 18, 2019.
-----------------------------------------------------------------


Additional Highlights